Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma

NCT07710690 is registered in ClinicalTrials.gov with Neuregen Therapeutics Co., Ltd. as lead sponsor.

NCT NCT07710690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07710690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma
Lead sponsor
Neuregen Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
July 9, 2026
Completion date
April 30, 2030
Enrollment
24 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hgg, high grade glioma, high grade glioma (iii or iv)